Experimental studies on ErbB targeted therapy in malignant melanoma

The ligands to PD-1, programmed death-ligands 1 and 2 (PD-L1, PD-L2), are not only expressed on myeloid cells, but can also be upregulated on cells not part of the immune system.

It was seen that melanoma patients who harboured a high fraction of activated and antigen- specific cytotoxic CD8+ T cells in blood and in tumours prior to ILP and IHP were

1) To evaluate the use of the BRAF-MEK-inhibitors dabrafenib and trametinib in patients with metastatic melanoma at a single institution in a clinical setting. 2) To evaluate the

DOCTORAL THESIS SAHLGRENSKA ACADEMY 2016 Epidemiology of cutaneous malignant melanoma in Western Sweden Magdalena Claeson Magdalena Claeson, MD Department of Dermatology

In the Western Sweden population of patients with multiple primary melanomas, a significantly in- creased proportion of melanoma in situ was found among subsequent

Keywords: Cutaneous malignant melanoma, Epidemiology, Prevention, Incidence, Mortality, Multiple primary melanomas, Thin melanomas, System dynamics modelling. ISBN:

In concordance with this Graells et al found no significant association between increased microvessel densities and VEGF expression in melanoma.158 However, elevated levels

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Epidermal growth factor receptor mutations in non-small-cell lung